HK1054690A1 - Treatment of glycogen storage disease type ii - Google Patents

Treatment of glycogen storage disease type ii

Info

Publication number
HK1054690A1
HK1054690A1 HK03107002A HK03107002A HK1054690A1 HK 1054690 A1 HK1054690 A1 HK 1054690A1 HK 03107002 A HK03107002 A HK 03107002A HK 03107002 A HK03107002 A HK 03107002A HK 1054690 A1 HK1054690 A1 HK 1054690A1
Authority
HK
Hong Kong
Prior art keywords
storage disease
disease type
treatment
glycogen storage
glycogen
Prior art date
Application number
HK03107002A
Other languages
English (en)
Inventor
Yuan-Tsong Chen
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22818451&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1054690(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Duke filed Critical Univ Duke
Publication of HK1054690A1 publication Critical patent/HK1054690A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK03107002A 2000-07-18 2003-09-27 Treatment of glycogen storage disease type ii HK1054690A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21923700P 2000-07-18 2000-07-18
PCT/US2001/021651 WO2002005841A1 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type ii

Publications (1)

Publication Number Publication Date
HK1054690A1 true HK1054690A1 (en) 2003-12-12

Family

ID=22818451

Family Applications (3)

Application Number Title Priority Date Filing Date
HK03107002A HK1054690A1 (en) 2000-07-18 2003-09-27 Treatment of glycogen storage disease type ii
HK14112435.2A HK1197656A1 (zh) 2000-07-18 2007-11-03 糖原累積病 型的療法
HK07111945.6A HK1103363A1 (en) 2000-07-18 2007-11-03 Treatment of glycogen storage diseases type ii ii

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK14112435.2A HK1197656A1 (zh) 2000-07-18 2007-11-03 糖原累積病 型的療法
HK07111945.6A HK1103363A1 (en) 2000-07-18 2007-11-03 Treatment of glycogen storage diseases type ii ii

Country Status (18)

Country Link
US (10) US7056712B2 (pt)
EP (4) EP1301201B1 (pt)
JP (10) JP5113312B2 (pt)
AT (1) ATE355075T1 (pt)
AU (3) AU2001271941B2 (pt)
BR (1) BR0113006A (pt)
CA (1) CA2416492C (pt)
CY (2) CY1120977T1 (pt)
DE (1) DE60126947T2 (pt)
DK (5) DK1782825T3 (pt)
ES (5) ES2799882T3 (pt)
HK (3) HK1054690A1 (pt)
LT (3) LT3108895T (pt)
MX (1) MXPA03000474A (pt)
PT (5) PT2767291T (pt)
SI (3) SI3449934T1 (pt)
TW (1) TWI280882B (pt)
WO (1) WO2002005841A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3449934T1 (sl) * 2000-07-18 2020-09-30 Duke University Zdravljenje bolezni kopičenja glikogena tip II
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
DE60224816T2 (de) * 2001-04-30 2009-01-22 ZyStor Therapeutics, Inc., Milwaukee Subzelluläres targeting von therapeutischen proteinen
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
WO2004064750A2 (en) 2003-01-22 2004-08-05 Duke University Improved constructs for expressing lysosomal polypeptides
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
ATE465250T1 (de) * 2004-02-10 2010-05-15 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
JP2008503590A (ja) * 2004-06-21 2008-02-07 メドトロニック・インコーポレーテッド 組成物を細胞にデリバリーするための医学用システム及び方法
WO2008063511A2 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
JP5627571B2 (ja) 2008-05-07 2014-11-19 バイオマリン ファーマシューティカル インコーポレイテッド リソソーム標的化ペプチドおよびその使用
DK2318037T3 (en) 2008-07-08 2015-05-04 Univ Duke Method for treating a glycogen storage-DISEASE
EP2475376B1 (en) * 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
US8809282B2 (en) 2010-05-06 2014-08-19 Duke University Method of reducing titers of antibodies specific for a therapeutic agent
CN105189542A (zh) 2013-02-20 2015-12-23 瓦莱里昂治疗有限责任公司 用于治疗庞贝氏症的方法和组合物
EP3622821A1 (en) * 2013-05-15 2020-03-18 Regents of the University of Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
CA2961762C (en) 2014-09-30 2024-03-05 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates
EP3292871B1 (en) * 2015-05-07 2021-06-23 The University of Tokyo Nanoreactor using polyion complex polymersomes, and method for producing same
CA2996906A1 (en) * 2015-08-31 2017-03-09 Duke University Methods and compositions for the treatment of cytoplasmic glycogen storage disorders
US10940125B2 (en) 2015-09-18 2021-03-09 Duke University Methods and compositions for the treatment of steatosis-associated disorders
SG11201804965SA (en) 2015-12-30 2018-07-30 Amicus Therapeutics Inc Augmented acid alpha-glucosidase for the treatment of pompe disease
JP7046003B2 (ja) 2016-03-30 2022-04-01 アミカス セラピューティックス インコーポレイテッド 高ｍ６ｐ組換えタンパク質の選択方法
KR20240001291A (ko) 2016-03-30 2024-01-03 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
AU2017250298A1 (en) 2016-04-15 2018-10-11 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type II
AU2018335752A1 (en) 2017-09-22 2020-03-12 Christian HINDERER Gene therapy for treating Mucopolysaccharidosis type ii
WO2020163480A1 (en) * 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3063911A (en) * 1961-04-03 1962-11-13 Taisho Pharmaceutical Co Ltd Acid-stable digestive enzyme preparation and process of making same
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
CN1300323A (zh) 1998-05-13 2001-06-20 加州大学洛杉矶分校港口研究和教育院 重组α－L－艾杜糖苷酸酶,其生产和纯化的方法以及治疗其缺乏导致的疾病的方法
DK2020438T3 (en) * 1998-12-07 2018-07-23 Genzyme Corp Treatment of Pompe disease
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
SI3449934T1 (sl) 2000-07-18 2020-09-30 Duke University Zdravljenje bolezni kopičenja glikogena tip II
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
ATE465250T1 (de) * 2004-02-10 2010-05-15 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture

Also Published As

Publication number Publication date
DK1782825T3 (da) 2014-11-03
JP2020019822A (ja) 2020-02-06
DK3449934T3 (da) 2020-06-29
SI2767291T1 (sl) 2016-11-30
TWI280882B (en) 2007-05-11
US20020110551A1 (en) 2002-08-15
LT3108895T (lt) 2018-11-26
EP3449934A1 (en) 2019-03-06
JP2018002749A (ja) 2018-01-11
CA2416492C (en) 2008-04-29
CY1123084T1 (el) 2021-10-29
CA2416492A1 (en) 2002-01-24
EP3449934B1 (en) 2020-05-20
DE60126947T2 (de) 2007-10-31
EP2767291A3 (en) 2014-10-08
DE60126947D1 (de) 2007-04-12
US20120058132A1 (en) 2012-03-08
MXPA03000474A (es) 2003-10-06
ES2523024T3 (es) 2014-11-20
LT2767291T (lt) 2016-11-25
US9907839B2 (en) 2018-03-06
US8900552B2 (en) 2014-12-02
ES2700865T3 (es) 2019-02-19
US20160184410A1 (en) 2016-06-30
JP2012006953A (ja) 2012-01-12
PT2767291T (pt) 2016-10-25
JP6163216B2 (ja) 2017-07-12
PT3108895T (pt) 2018-12-18
JP2008081507A (ja) 2008-04-10
EP3108895A1 (en) 2016-12-28
ES2599401T3 (es) 2017-02-01
PT1301201E (pt) 2007-03-30
US20180185457A1 (en) 2018-07-05
SI3449934T1 (sl) 2020-09-30
US10792341B2 (en) 2020-10-06
AU2010200487A1 (en) 2010-03-04
HK1197656A1 (zh) 2015-02-06
JP5792774B2 (ja) 2015-10-14
PT3449934T (pt) 2020-06-25
US20130195834A1 (en) 2013-08-01
LT3449934T (lt) 2020-08-10
DK3108895T3 (en) 2018-11-26
US20080175833A1 (en) 2008-07-24
ES2799882T3 (es) 2020-12-22
JP5113312B2 (ja) 2013-01-09
BR0113006A (pt) 2004-10-19
US20100254966A1 (en) 2010-10-07
EP2767291A2 (en) 2014-08-20
EP3108895B1 (en) 2018-09-19
WO2002005841A1 (en) 2002-01-24
PT1782825E (pt) 2014-11-04
AU7194101A (en) 2002-01-30
JP2018199721A (ja) 2018-12-20
JP2017137357A (ja) 2017-08-10
CY1120977T1 (el) 2019-12-11
JP2016056206A (ja) 2016-04-21
US20150004152A1 (en) 2015-01-01
US7056712B2 (en) 2006-06-06
SI3108895T1 (sl) 2019-01-31
US20210169996A1 (en) 2021-06-10
US9370556B2 (en) 2016-06-21
DK1301201T3 (da) 2007-04-02
EP1301201A1 (en) 2003-04-16
JP2004503598A (ja) 2004-02-05
JP2013231081A (ja) 2013-11-14
HK1103363A1 (en) 2007-12-21
DK2767291T3 (en) 2016-12-05
US20050123531A1 (en) 2005-06-09
EP1301201B1 (en) 2007-02-28
JP2014185187A (ja) 2014-10-02
ES2277931T3 (es) 2007-08-01
EP2767291B1 (en) 2016-09-14
ATE355075T1 (de) 2006-03-15
AU2001271941B2 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
GB0223038D0 (en) Therapeutic compounds
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
HK1047707A1 (zh) (+)-曲馬朵、o-去甲曲馬朵或(+)-o-去甲曲馬朵、o-去甲-n-單-去甲-曲馬朵或(+)-o-去甲-n-單-去甲-曲馬朵治療尿失禁的用途
GB0211247D0 (en) Compositions and methods for treating or preventing convulsions or seizures
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
DE60142899D1 (de) Verbindungen für den transfer von oligonukleotiden
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen
WO2002076400A3 (en) Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
EP1782825A3 (en) Treatment of glycogen storage diseases type II
WO2002051404A8 (fr) Compositions orales
UA29106A (uk) Спосіб лікування вібраційної хвороби
UA31369A (uk) Спосіб покращання кровотоку пілородуоденальної зони
UA34199A (uk) Спосіб лікування пародонтиту

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20210709